nach oben

Drugs

Erschienen in:

01.05.2004 | Adis Drug Profile

Micafungin

verfasst von: Blair Jarvis, David P. Figgitt, Lesley J. Scott

Erschienen in: Drugs | Ausgabe 9/2004

Einloggen, um Zugang zu erhalten

Abstract

▴ Micafungin, an echinocandin antifungal agent with a novel mechanism of action, inhibits β-(l,3)-D-glucan synthase interfering with fungal cell wall synthesis. It shows excellent antifungal activity against a broad range of Candida spp., including azole-resistant strains, and Aspergillus spp. in in vitro and animal studies.
▴ In HIV-positive patients, intravenous micafungin 50–150 mg/day dose-dependently eradicated endoscopically confirmed oesophageal candidiasis, with micafungin 100 and 150 mg/day being more effective than micafungin 50 mg/day and as effective as fluconazole 200 mg/day in a double-blind trial.
▴ In nonblind trials, micafungin (monotherapy or combination therapy) was effective against invasive aspergillosis, candidiasis and candidaemia in paediatric and adult patients with newly diagnosed or refractory infections.
▴ Micafungin 50 mg/day provided significantly better antifungal prophylaxis than fluconazole 400 mg/ day in 882 haematopoietic stem cell transplant recipients in a randomised, double-blind trial. Respective overall success rates were 80% and 73.5%.
▴ Micafungin is generally well tolerated. Adverse events were not dose- or infusion-related with micafungin 12.5–900 mg/day; no histamine-like reactions occurred. Micafungin was as well tolerated as fluconazole, with numerically fewer micafungin recipients discontinuing treatment (4.2% vs 7.2%).

Arathoon EG. Clinical efficacy of echinocandin antifungals. Curr Opin Infect Dis 2001 Dec; 14(6): 685–91PubMedCrossRef

O’Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. MMWR 2002; 51(RR10): 1–26PubMed

Graybill JR. Hitting a new target with echinocandins: why chase something else? Curr Opin Invest Drug 2001; 2(4): 468–71

Groll AH, Walsh TJ. FK-463 Fujisawa Pharmaceutical Co Ltd. Curr Opin Anti-Infect Invest Drugs 2000; 2(4): 405–12

Nishiyama Y, Uchida K, Yamaguchi H. Morphological changes of Candida albicans induced by micafungin (FK463), a water-soluble echinocandin-like lipopeptide. J Electron Microsc (Tokyo) 2002; 51(4): 247–55CrossRef

Rex JH, Pfaller MA, Walsh TJ, et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 2001; 14(4): 643–58PubMedCrossRef

Müller FM, Kurzai O, Hacker J, et al. Effect of the growth medium on the in vitro antifungal activity of micafungin (FK-463) against clinical isolates of Candida dubliniensis. J Antimicrob Chemother 2001 Nov; 48(5): 713–5PubMedCrossRef

Tomishima M, Ohki H, Yamada A, et al. FK463, a novel water-soluble echinocandin lipopeptide: synthesis and antifungal activity [letter]. J Antibiot (Tokyo) 1999 Jul; 52(7): 674–6CrossRef

Mikamo H, Sato Y, Tamaya T. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. J Antimicrob Chemother 2000 Sep; 46(3): 485–7PubMedCrossRef

10.

Laverdiere M, Hoban D, Restieri C, et al. In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J Antimicrob Chemother 2002 Jul; 50(1): 119–23PubMedCrossRef

11.

Tawara S, Ikeda F, Maki K, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000 Jan; 44(1): 57–62PubMedCrossRef

12.

Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003 Oct; 47(10): 3149–54PubMedCrossRef

13.

Uchida K, Nishiyama Y, Yokota N, et al. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens. J Antibiot (Tokyo) 2000 Oct; 53(10): 1175–81CrossRef

14.

Nakai T, Uno J, Ikeda F, et al. In vitro antifungal activity of micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms. Antimicrob Agents Chemother 2003 Apr; 47(4): 1376–81PubMedCrossRef

15.

Stevens DA. Drug interaction in vitro between a polyene (AmBisone; Ambi) and an echinocandin (FK463; FK) vs. Aspergillus species. Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–30; San Francisco, 543

16.

Ostrosky-Zeichner L, Matar M, Paetznick VL, et al. In-vitro synergy testing of anidulafungin (AFG) and micafungin (MFG) in combination with amphotericin B (AMB) against Aspergillus spp. and Fusarium spp. [abstract no. M-1816] Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27–30; San Diego

17.

Manavathu EK, Ganesan LT, Cutright PH, et al. In vitro antifungal activity of voriconazole in two-drug combination with micafungin, caspofungin and amphotericin B [abstract no. J-125]. Proceedings of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Dec 16–19; Chicago

18.

Chiou CC, Mavrogiorgos N, Tillem E, et al. Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus. Antimicrob Agents Chemother 2001 Dec; 45(12): 3310–21PubMedCrossRef

19.

O’Shaughnessy EM, Peter J, Walsh TJ. In vitro additive and synergistic effect of two echinocandins, caspofungin and micafungin with voriconazole against Aspergillus fumigatus [abstract no. M-856]. Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27–30; San Diego

20.

Ernst EJ, Roling EE, Petzold CR, et al. In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob Agents Chemother 2002 Dec; 46(12): 3846–53PubMedCrossRef

21.

Manavathu EK, Ramesh MS, Baskaran I, et al. A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans. J Antimicrob Chemother 2004 Feb; 53(2): 386–9PubMedCrossRef

22.

Kuhn DM, George T, Chandra J, et al. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002 Jun; 46(6): 1773–80PubMedCrossRef

23.

Borg-Von Zepelin M, Zaschke K, Gross U, et al. Effect of micafungin (FK463) on Candida albicans adherence to epithelial cells. Chemotherapy 2002 Jul; 48(3): 148–53PubMedCrossRef

24.

Maesaki S, Hossain MA, Miyazaki Y, et al. Efficacy of FK463, a (l,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant Candida albicans infection in mice. Antimicrob Agents Chemother 2000 Jun; 44(6): 1728–30PubMedCrossRef

25.

Ikeda F, Wakai Y, Matsumoto S, et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother 2000 Mar; 44(3): 614–8PubMedCrossRef

26.

Warn PA, Sharp A, Morrissey G, et al. In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis. J Antimicrob Chemother 2002 Dec; 50(6): 1071–4PubMedCrossRef

27.

Warn PA, Morrissey G, Morrissey J, et al. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B. J Antimicrob Chemother 2003; 51: 913–9PubMedCrossRef

28.

Luque JC, Clemons KV, Stevens DA. Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob Agents Chemother 2003 Apr; 47(4): 1452–5PubMedCrossRef

29.

Matsumoto S, Wakai Y, Nakai T, et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis. Antimicrob Agents Chemother 2000 Mar; 44(3): 619–21PubMedCrossRef

30.

Kohno S, Maesaki S, Iwakawa J, et al. Synergistic effects of combination of FK463 with amphotericin B: enhanced efficacy in murine model of invasive pulmonary aspergillosis [abstract no. 1686]. Proceedings of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto

31.

Petraitis V, Petraitiene R, Groll AH, et al. Comparative anti-fungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2002 Jun; 46(6): 1857–69PubMedCrossRef

32.

Ito M, Nozu R, Kuramochi T, et al. Prophylactic effect of FK463, a novel antifungal lipopeptide, against Pneumocystis carinii infection in mice. Antimicrob Agents Chemother 2000 Sep; 44(9): 2259–62PubMedCrossRef

33.

Tawara S, Nakai T, Matsumoto K, et al. Effect of micafungin and caspofungin on histamine release, blood pressure and heart rate in rats [abstract no. 29]. Proceedings of the 12th Annual Focus on Fungal Infections Meeting; 2002 Mar 14–16; Phoenix

34.

Groll AH, Mickiene D, Petraitis V, et al. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob Agents Chemother 2001 Dec; 45(12): 3322–7PubMedCrossRef

35.

Suzuki S, Terakawa M, Yokobayashi F, et al. Pharmacokinetics of FK463, a novel water-soluble echinocandin-like lipopeptide, in animals [abstract no. F-144]. Proceedings of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–27; San Diego, 269

36.

Azuma J, Yamamoto I, Ogura M, et al. Phase I study of FK463, a new antifungal agent, in healthy adult male volunteers [abstract no. F-146]. Proceedings of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–27; San Diego, 269

37.

Townsend R, Terakawa M, Bekersky I. PK/disposition of ¹⁴C/ FK463, a novel echinocandin antifungal, in male volunteers [abstract]. J Clin Pharmacol 2000 Sep; 40: 1048

38.

Mukai T, Ohkuma T, Nakahara K, et al. Pharmacokinetics of FK463, a novel echinocandin analogue, in elderly and non-elderly subjects [abstract]. Proceedings of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Dec 15–19; Chicago

39.

Townsend R, Hebert M, Wisemandle W, et al. Concomitant pharmacokinetics (PK) of micafungin, an echinocandin antifungal, and tacrolimus in healthy volunteers [abstract]. Proceedings of the 31st Annual Meeting of the American College of Clinical Pharmacology; 2002 Sep 21–23; San Francisco

40.

Townsend R, Hebert M, Wisemandle W, et al. Concomitant pharmacokinetics (PK) of micafungin, an echinocandin antifungal, and cyclosporine in healthy volunteers [abstract]. Proceedings of the 31st Annual Meeting of the American College of Clinical Pharmacology; 2002 Sep 21–23; San Francisco

41.

Townsend R, Bekersky I, Buell DN, et al. Pharmacokinetic (PK) evaluation of echinocandin FK463 in pediatric and adult patients [abstract no. 024]. Proceedings of the 11th Focus on Fungal Infections Meeting; 2001 Mar 14–16; Washington, DC

42.

Heresi GP, Gertsmann DR, Blumer JL, et al. Pharmacokinetic, safety, and tolerance study of micafungin (FK463) in premature infants [abstract]. Proceedings of the Pediatric Academic Societies Annual Meeting; 2003 May 3–6; Seattle

43.

Hiemenz J, Cagnoni P, Simpson D, et al. Maximum tolerated dose and pharmacokinetics of FK463 in combination with fluconazole for the prophylaxis of fungal infections in adult bone marrow or peripheral stem cell transplant patients [abstract]. Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–30; San Francisco, 576

44.

Townsend R, Terakawa M, Bekersky I. Pharmacokinetics of FK463, a novel echinocandin antifungal, in bone marrow or peripheral stem cell transplant patients [abstract]. J Clin Pharmacol 2000 Sep; 40: 1049

45.

Townsend R, Hebert M, Dessimoz M, et al. Pharmacokinetics (PK) of micafungin, an echinocandin antifungal, in subjects with severe renal dysfunction [abstract]. Proceedings of the 31st Annual Meeting of the American College of Clinical Pharmacology; 2002 Sep 21–23; San Francisco

46.

Townsend R, Hebert M, Dessimoz M, et al. Pharmacokinetics (PK) of micafungin, an echinocandin antifungal, in subjects with moderate hepatic dysfunction (MHD) [abstract]. Proceedings of the 31st Annual Meeting of the American College of Clinical Pharmacology; 2002 Sep 21–23; San Francisco

47.

Seibel N, Schwartz C, Arrieta A, et al. A phase I study to determine the safety and pharmacokinetics of FK463 (echinocandin) in febrile neutropenic pediatric patients [abstract no. 18]. Proceedings of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto

48.

Kohno S, Masaoka T, Yamaguchi H. A multicenter, open-label clinical study of FK463 in patients with deep mycosis in Japan [abstract]. Proceedings of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Dec 16–19; Chicago

49.

Kontoyiannis DP, Buell D, Frisbee-Hume S, et al. Initial experience with FK-463 for the treatment of candidemia in cancer patients [abstract no. J-1629]. Proceedings of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Dec 16–19; Chicago, 394

50.

Ullmann AJ, Van Burik JA, McSweeney P, et al. An open phase II study of the efficacy of micafungin (FK463) alone and in combination for the treatment of invasive aspergillosis (IA) in adults and children [abstract no. 0400]. Clin Microbiol Infect 2003; 9 (6)

51.

Ratanatharathorn V, Flynn P, Van Burik J-A, et al. Micafungin in combination with systemic antifungal agents in the treatment of refractory aspergillosis (RA) in bone marrow transplant (BMT) patients [abstract no. 2472]. Proceedings of the 44th Annual Meeting of the American Society of Hematology; 2002 Dec 6–10; Philadelphia

52.

De Wet NTE, Llanos-Cuentas A, Suleiman H, et al. Micafungin (FK463) dose response and comparison with fluconazole in oesophageal candidiasis [abstract no. M-1754]. Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago

53.

Pettengell K, MynhardtJ, Kluyts T, et al. A multicenter study of the echinocandin antifungal FK463 for the treatment of esophageal candidiasis in HIV positive patients [abstract]. Proceedings of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto, 371

54.

Pettengell K, MynhardtJ, Kluyts T, et al. A multicenter study to determine the minimal effective dose of FK463 for the treatment of esophageal candidiasis in HIV-positive patients [abstract]. Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29; San Francisco, 567

55.

Suleiman J, Delia Negra M, Llanos-Cuentas A, et al. Open label study of micafungin in the treatment of esophageal candidiasis (EC) [abstract no. M-892]. Proceedings of the 42nd Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27–30; San Diego

56.

Powles R, Sirohi B, Chopra R, et al. Assessment of maximum tolerated dose and pharmacokinetics of FK463 in neutropenic patients after haematopoietic stem cell transplantation [abstract]. Blood 2001 Nov 16; 98 (Pt 2): 361

57.

Powles R, Sirohi B, Chopra R, et al. Use of FK 463, a novel echinocandin analog in patients undergoing stem cell transplantation (SCT) for hematologic malignancies, a matched pair comparison of biochemical toxicity with historical controls [abstract]. Bone Marrow Transplant 2002 Mar; 29 Suppl. 2: S247

58.

Anaissie E, Kontoyiannia D, Raffali J, et al. Micafungin (MCFG), an echinocandin antifungal agent for the treatment of new and refractory candidemia [abstract no. P-35]. Proceedings of the 13th Annual Focus on Fungal Infections Meeting; 2003 Mar 19–21; Maui (HI)

59.

Van Burik J, Ratanatharathorn V, Lipton J, et al. Randomized, double-blind trial of micafungin (MI) versus fluconazole (FL) for prophylaxis of invasive fungal infections in patients (pts) undergoing hematopoietic stem cell transplant (HSCT), NIAID/BAMSG protocol 46 [abstract no. M-1238]. Proceedings of the 42nd Interscience conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27–30; San Diego

60.

Kemper M, Weinstein A, Frame D, et al. Incidence and consequences of nephrotoxicity in HSCT treated with empiric amphotericin, micafungin or no anti-fungal agent [abstract no. P-49]. Proceedings of the 13th Annual Focus on Fungal Infections Meeting; 2003 Mar 19–21; Maui (HI)

61.

Fujisawa Pharmaceutical Co., Ltd. Funguard® for infusion 50mg. Funguard® for infusion 75mg [prescribing information]. Japan: Fujisawa Pharmaceutical Co. Ltd, 2003

62.

Japanese premium for micafungin. Scrip 2002 Dec; 2806: 22

63.

Fujisawa Healthcare Inc. Fujisawa Healthcare, Inc. submits NDA for new antifungal product [online]. Available from URL: http://www.fujisawa.com [Accessed 2002 Aug 8]

64.

Fujisawa GmbH. Fujisawa GmbH submits new antifungal drug in Europe [online]. Available from URL: http://www.fujisawaeurope.com [Accessed 2003 Mar 1]

Titel: Micafungin
verfasst von: Blair Jarvis
David P. Figgitt
Lesley J. Scott
Publikationsdatum: 01.05.2004
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 9/2004
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200464090-00004

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Micafungin

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2004

Lanthanum Carbonate

Glycopeptide Antibiotics

Lanthanum Carbonate

Micafungin

Lanthanum Carbonate

Review of Lidocaine Patch 5% Studies in the Treatment of Postherpetic Neuralgia